x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012335
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human NAT10 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | NAT10 |
| UniProt No. | Q9H0A0 |
| Gene ID | 55226 |
| Gene Description | N-acetyltransferase 10, also known as human N-acetyltransferase-like protein, is an acetyltransferase which increases telomerase activity through the activation of the TERT promoter. NAT10 localizes to the midbody in late phase mitosis to help achieve cytokinesis. It has been found that DNA damage can actually increase NAT10-dependent acetylation of alpha-tubulin, resulting in increased stability of the protein. This increased stability of microtubules has been linked to the sequestration of the nuclear import factor Transportin-1 in the premature aging disease, progeria. NAT10 can also function as an acetyltransferase for both rRNA and mRNA. The acetylation of the 18 S rRNA helps in rRNA processing and ribosome biogenesis, and this process can be disrupted by opposing activity of the deacetylase SirT1 in response to stress. mRNA acetylation by NAT10 plays a role in translation efficiency and mRNA stability. NAT10 is overexpressed in many different cancer types, making it a good potential therapeutic target |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
